<DOC>
	<DOC>NCT03054818</DOC>
	<brief_summary>This is a post-marketing drug safety monitoring study in a prospective manner, and data collection will be performed in a registration-follow-up manner. Safety information about patients who have received intravitreal injection of Conbercept Ophthalmic Injection in medical institutions involved in the study during research will be actively monitored without intervening in diagnosis and treatment. All patients enrolled will be followed up for one year.</brief_summary>
	<brief_title>Safety Evaluation of China Patients: Long-term Treatment Outcome of Conbercept Ophthalmic Injection in Real Word（STONE）</brief_title>
	<detailed_description />
	<mesh_term>Macular Degeneration</mesh_term>
	<criteria>1. The condition that informed consent has been freely given prior to researchrelated procedures; 2. Patients who have received at least one intravitreal injection of Conbercept Ophthalmic Injection after informed consent has been given. 1. Patients who have been on any of other antiVEGF drugs systematically or locally, including but not limited to bevacizumab, ranibizumab and aflibercept, 90 days before enrollment; 2. Those who are on other study drugs or have been on other study drugs 30 before informed consent is given.</criteria>
	<gender>All</gender>
	<minimum_age>N/A</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>February 2017</verification_date>
</DOC>